Here's a roundup of top developments in the biotech space over the last 24 hours:Scaling The Peaks (Biotech stocks hitting 52-week highs April 23.) * Arcturus Therapeutics Ltd (NASDAQ: ARCT) * Chembio Diagnostics Inc (NASDAQ: CEMI) * Cue Biopharma Inc (NASDAQ: CUE) * Eli Lilly And Co (NYSE: LLY) (reported strong Q1 results) * Exelixis, Inc. (NASDAQ: EXEL) * GenMark Diagnostics, Inc (NASDAQ: GNMK) * Halozyme Therapeutics, Inc. (NASDAQ: HALO) * Immunomedics, Inc. (NASDAQ: IMMU) (announced FDA nod for its ADC to treat triple-negative breast cancer) * Incyte Corporation (NASDAQ: INCY) (announced publication of positive data for Jakafi in acute graft-versus-host disease) * Iovance Biotherapeutics Inc (NASDAQ: IOVA) * Johnson & Johnson (NYSE: JNJ) * Novo Nordisk A/S (NYSE: NVO) * OraSure Technologies, Inc. (NASDAQ: OSUR) * Pluristem Therapeutics Inc. (NASDAQ: PSTI) (announced advancement of its placental cells to modulate cytokine storm) * Quidel Corporation (NASDAQ: QDEL) (filed with the FDA...
With earnings coming out next week, should you buy Ford (NYSE:F)? The automaker has seen its share of trouble from the novel coronavirus. With its auto plants sitting idle, expect them to continue burning through cash until we get back to "normal," which doesn't bode well for F stock.Source: Vitaliy Karimov / Shutterstock.com Based on numbers recently released by the company, cash burn could be over $5 billion per month. The automaker has built up a solid cash position to ride things out. But, let's just say 2020 isn't going to be a great year financially.So, why buy F stock? Especially now, just before earnings? Despite the plethora of bad news, shares today could be "priced for disaster."InvestorPlace - Stock Market News, Stock Advice & Trading TipsIn other words, shares may have been oversold relative to actual risks. Sure, shares could go lower in the near-term. But one to two years...
Penn National Gaming (NASDAQ:PENN) is up nearly 40% in the last 30 days. This is welcome news to investors who watched as PENN stock fell nearly 90% in the period between February 20 through March 20.Source: Jeffrey J Coleman / Shutterstock.com Investors are obviously encouraged by the fact that Penn National, and other casinos, will receive a lifeline from the federal government. But a recent Macquarie Research report showed that Penn is burning through cash at a rate that would only keep the company afloat for five months.Prior to the coronavirus pandemic, PENN was building a nice poker hand. They had an "asset light" infrastructure that was allowing the company to collect rent on many of its various properties. And a new agreement with Barstool Sports was giving the company an important foothold in the lucrative sports betting industry.InvestorPlace - Stock Market News, Stock Advice & Trading TipsBut investing in casino...
On April 16, the $349 billion first round of the government’s Paycheck Protection Program (PPP) for small business coronavirus relief loans ran out of money after just 13 days....
AT&T (NYSE:T) looks like an oil company stock, with a yield that looks too good to be true. As trading opened April 23 AT&T stock was as trading at $29.50.Source: Roman Tiraspolsky / Shutterstock.com Its 52-cent-per-share dividend now yields 7% if you buy now. By way of comparison, Chevron (NYSE:CVX), the second-largest U.S. oil company, has a yield of 6.3%.The market considers AT&T a classic "yield trap." That's a stock that attracts income investors but isn't may not be good for its promised income. It ended the March quarter with $147 billion of long-term debt. The capital spending budget is $5 billion/quarter. The dividend costs $3.7 billion/quarter.InvestorPlace - Stock Market News, Stock Advice & Trading TipsFree cash flow for the quarter was $3.9 billion. Management insists it's committed to the dividend. Is AT&T Stock a Trap?Things could get worse. They are getting worse. AT&T lost nearly 900,000 premium TV subscribers during...
Stock futures kicked off the overnight session roughly flat on the heels of a volatile trading day Thursday, with stocks whipsawed amid conflicting signals over the results of a clinical trial for a coronavirus antiviral treatment candidate....
